Study on Olaparib for Treating Advanced Glioma, Cholangiocarcinoma, or Solid Tumors with IDH1 or IDH2 Mutations

Inclusion Criteria

• Must understand the study and agree to participate, with the option for a caregiver to assist if needed.
• Diagnosed with glioma, cholangiocarcinoma, or another solid tumor that has specific IDH1 or IDH2 mutations and has not responded to standard treatments.
• Tumors must be accessible for biopsy, and patients must agree to have biopsies done.
• Must be willing to provide extra blood samples for research.
• Must have measurable disease based on specific medical criteria.
• For glioma patients, specific criteria about the tumor's progression and treatment history apply.
• Must be 18 years or older.
• Must have good overall health and specific blood test results within normal ranges.
• Must not have had previous treatment with olaparib or similar drugs.
• Women of childbearing potential must use effective contraception during the study and for one month after.
• Men must agree to use contraception during the study and for three months after.

Exclusion Criteria

• Cannot participate if involved in planning or conducting the study.
• Cannot have participated in another clinical study with an investigational product recently.
• Cannot have had previous treatment with PARP inhibitors like olaparib.
• Cannot have other active cancers within the last five years, with some exceptions.
• Cannot have certain heart conditions or be taking specific medications that interact with olaparib.
• Cannot have unresolved side effects from previous cancer treatments.
• Cannot have uncontrolled brain metastases or other serious medical conditions.
• Cannot be pregnant or breastfeeding.
• Cannot have certain infections like active hepatitis or HIV.
• Cannot have had a recent major surgery or certain blood transfusions.
• Cannot have a history of allergic reactions to olaparib or similar drugs.